Physician profile
Timothy Moran
NPI 1639313513
$2,820.46
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $45.01 · 2021: $144 · 2022: $1,442 · 2023: $605 · 2024: $78.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.94 | 2019-2023 | Ozempic |
| Tandem Diabetes Care, INC. | $525.38 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $203.98 | 2022-2023 | Lyumjev, Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $194.95 | 2022-2023 | |
| Insulet Corporation | $165.83 | 2022-2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $114.75 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.85 | 2022-2023 | Jardiance |
| Dexcom, INC. | $105.66 | 2022-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $94.00 | 2022-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $81.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $75.77 | 2022 | |
| Amneal Pharmaceuticals LLC | $63.25 | 2022-2023 | Unithroid |
| Becton, Dickinson and Company | $50.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.99 | 2020-2022 | |
| Medtronic, INC. | $43.83 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $38.81 | 2022 | |
| Grt US Holding, INC. | $33.58 | 2022 | |
| Mannkind Corporation | $31.37 | 2022 | |
| Abbvie INC. | $28.23 | 2023 | |
| Abbott Laboratories | $26.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.99 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.23 | 2023 | Gattex |
| Ipsen Biopharmaceuticals, INC | $23.42 | 2022 | |
| Antares Pharma, INC. | $22.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.24 | 2023 | Strensiq |
| Pfizer INC. | $20.84 | 2023 | |
| Zealand Pharma US, INC. | $18.69 | 2022 | |
| Amgen INC. | $17.82 | 2023 | Repatha |
| Acella Pharmaceuticals, LLC | $17.19 | 2021 | |
| Ascensia Diabetes Care US INC. | $14.47 | 2022 | |
| Medtronic Minimed, INC. | $13.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.